Today, we have a special conversation with Dr. Praveen Raj, Head of Medical Affairs, who recently represented Biocon Biologics at the prestigious International Diabetes Federation (IDF) Congress. IDF is a global platform where researchers, clinicians, and industry leaders from around the world share the latest advancements in diabetes care. This year, Biocon Biologics presented six … Continue reading In Conversation with Dr. Praveen Raj for IDF, Thailand
Biocon Biologics Opens North America Headquarters in New Jersey’s Biopharma Corridor
Biocon Biologics proudly celebrated a significant milestone with the official opening of its new North America headquarters in Bridgewater, New Jersey, on Friday, September 13. This occasion also marked the Company’s first-year anniversary in the region, further solidifying its commitment to providing high-quality, affordable biosimilar medicines to patients in North America and across the globe. … Continue reading Biocon Biologics Opens North America Headquarters in New Jersey’s Biopharma Corridor
Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
The successful integration of the acquired Biosimilars business dominated the Biocon Biologics growth story last year. In fiscal year 2024-25 (FY25), we have turned our focus to consolidating the acquired business and paving the way for future growth. Our performance in the first quarter of FY25 gives us confidence that we are on the right … Continue reading Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
Biocon Biologics Marks Another Key Milestone with Successful Transition of the North America Business Ahead of Plan
Biocon Biologics marked a key milestone in the post-acquisition integration of the biosimilars business of its long-term partner Viatris with the successful transitioning of the business in North America (United States and Canada) on September 1, 2023. It marks Biocon Biologics’ first direct commercial presence in Advanced Markets and represents the largest share of its … Continue reading Biocon Biologics Marks Another Key Milestone with Successful Transition of the North America Business Ahead of Plan
Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Biocon Biologics’ (BBL) revenues for Q1 FY24 saw an over 100% year-on-year growth, driven by the consolidation of the biosimilars business acquired from Viatris, as well as higher sales of commercialized products that is reflected in their market share gains in U.S. & Europe. The robust performance this quarter has given Biocon Biologics the impetus … Continue reading Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Biocon Biologics Ends FY23 on a $1 billion Annual Revenue Trajectory
Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league. BBL more than doubled its revenue on a YoY basis to Rs 2,102 crore … Continue reading Biocon Biologics Ends FY23 on a $1 billion Annual Revenue Trajectory
Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
The world is just emerging from the economic impact of the COVID-19 pandemic. The people who suffered the economic fallout of the pandemic as their incomes shrunk, urgently need of access to cheaper drugs. This has been the case not only in the emerging markets, but also in the developed countries. Generics and biosimilars which … Continue reading Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon developing 20 biosimilar products for global markets
India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets
‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’
Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon Biologics’ foray into vaccines and antibodies for … Continue reading ‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’
A Unique & Synergistic Alliance to Impact Global Health
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd, have entered into a historic alliance to impact global health. This alliance will complement the strengths and resources of two leading Indian players in addressing inequitable access both in … Continue reading A Unique & Synergistic Alliance to Impact Global Health
Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence
Dr. Sundar Ramanan, Global Head of Regulatory Affairs, Biocon Biologics Dr. Sundar Ramanan, Vice President & Head, Global Regulatory Affairs, Biocon Biologics, presented on behalf of the Company at the public meeting for the reauthorization process for the Biosimilar User Fee Act (BsUFA III) program organized by the U.S. Food and Drug Administration (FDA) on … Continue reading Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence
Early Insulinization Can be Key to Effective Diabetes Management
Diabetes is a global epidemic and the number of people with diabetes globally is growing at an alarming rate. An estimated 463 million adults (20-79 years), or about 1 in 11 adults worldwide, are living with diabetes across the world in 2019; by 2045 this will rise to 700 million1. Globally, the number of people … Continue reading Early Insulinization Can be Key to Effective Diabetes Management
A Disease of Halves: Why better patient adherence to treatment is important to manage diabetes?
Diabetes Mellitus is a major health issue with nearly half a billion people living with this ailment globally. Diabetes is a serious, chronic or long-term condition that occurs when there are elevated levels of glucose in a person’s blood because their body cannot produce any or enough of the hormone insulin, or cannot effectively use … Continue reading A Disease of Halves: Why better patient adherence to treatment is important to manage diabetes?
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents/Day for LMICs
Kiran Mazumdar Shaw speaks at the UNAIDS Health Innovation Exchange Meeting on the sidelines of United Nations General Assembly, held in New York on 25th September 2019. Your Excellencies, Distinguished Ladies and Gentlemen, We have just witnessed the first UN High Level meeting on Universal Health Care on Monday. Governments have a collective moral responsibility … Continue reading Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents/Day for LMICs
US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US
India and the U.S. are witnessing a deepening of ties with a convergence of views on many issues. India is rapidly emerging as a preferred economic and technology partner for the US. India IT and pharma companies have made significant investments and have created jobs in the US. These investments signal a growing economic interdependence … Continue reading US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US
A Blog by Biocon 